Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207825 | 1.00 | ESR2 (0.54) | ESR2NR1H2MAPK1ABHD6DDB1 | |
| SCHEMBL16730890 | 0.90 | ESR2 (0.54) | ESR2NR1H2MAPK1ABHD6DDB1 | |
| SCHEMBL19608875 | 0.86 | ESR2 (0.56) | ESR2NR1H2MAPK1ABHD6DDB1 | |
| SCHEMBL3693657 | 0.85 | ESR2 (0.59) | ESR2NR1H2MAPK1ABHD6DDB1 | |
| SCHEMBL30199091 | 0.85 | ESR2 (0.59) | ESR2NR1H2MAPK1ABHD6DDB1 | |
| SCHEMBL29801280 | 0.84 | ESR2 (0.54) | ESR2NR1H2MAPK1ABHD6DDB1 | |
| SCHEMBL20364333 | 0.84 | ESR2 (0.54) | ESR2NR1H2MAPK1ABHD6DDB1 | |
| SCHEMBL29734640 | 0.84 | ESR2 (0.54) | ESR2NR1H2MAPK1ABHD6DDB1 | |
| SCHEMBL4519564 | 0.84 | NR1H2 (0.60) | ESR2NR1H2MAPK1ABHD6DDB1 | |
| SCHEMBL29417735 | 0.84 | ABHD6 (0.65) | ESR2NR1H2MAPK1ABHD6DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552826-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-20210309687-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3833669-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3262057-B1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2020033285-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | WO | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| WO-2016135582-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | TYMP, NME1, DPYD | ESR2 3672/4885NR1H2 3470/4885MAPK1 3190/4885 |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | ESR2 3795/4885NR1H2 3470/4885MAPK1 2497/4885 |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | ESR2 2951/4885NR1H2 3021/4885MAPK1 3113/4885 |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | ESR2 2951/4885NR1H2 3021/4885MAPK1 3113/4885 |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | ESR2 2951/4885NR1H2 3021/4885MAPK1 3113/4885 |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | ESR2 2951/4885NR1H2 3021/4885MAPK1 3113/4885 |
| US-20210309687-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | ESR2 2400/4885NR1H2 698/4885MAPK1 1660/4885 |
| US-12552826-B2 | PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | ESR2 2969/4885NR1H2 322/4885MAPK1 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.